Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation

Rhea-AI Summary

Bioxytran (OTCQB: BIXT) announced a significant scientific advancement with the publication of a groundbreaking book by Prof. Avraham Mayevsky on tissue oxygenation and mitochondrial function. The research highlights the limitations of current peripheral oxygen measurements and introduces a paradigm shift towards tissue-specific oxygenation monitoring.

The company's MDX Viewer technology, combined with their Universal Oxygen Carrier (UOC) and BXT-25 development programs, aims to revolutionize treatment approaches for conditions like stroke and Alzheimer's disease. The technology will serve as a crucial biomarker in upcoming BXT-25 clinical trials, potentially transforming how oxygen delivery is measured and managed in critical conditions.

Positive

• Development of advanced tissue-specific oxygenation monitoring technology
• Integration of MDX Viewer technology as a biomarker for BXT-25 clinical trials
• Potential applications in major markets including stroke and Alzheimer's treatment

Negative

• Clinical trials for BXT-25 still pending
• Technology remains in development phase with no immediate revenue generation

News Market Reaction

-4.99%

1 alert

-4.99% News Effect

On the day this news was published, BIXT declined 4.99%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

• Game changer for stroke, Alzheimer’s, and beyond 
• Shifting from peripheral to tissue-specific oxygenation monitoring

BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions.

https://link.springer.com/book/10.1007/978-3-031-94113-9

Current medical practices rely on outdated peripheral oxygen measurements, often missing the real crisis happening inside vital organs. Imagine a stroke patient with "100% oxygen saturation" while their brain suffocates—this is the alarming gap that Prof. Mayevsky’s research addresses. His book bridges cutting-edge animal studies with real-world clinical applications, offering a roadmap to Precision diagnostics. The book highlights how shifting from peripheral to tissue-specific oxygenation monitoring (via FDA-approved tools like the MDX Viewer) leads to better outcomes in the operating room. This Next-gen diagnostic is aligned with Bioxytran’s Universal Oxygen Carrier (UOC), designed to rescue oxygen-starved tissues in stroke and neurodegenerative diseases. 

Bioxytran is integrating these insights into its upcoming BXT-25 clinical trials, aiming to prove that targeted oxygen delivery can rescue damaged tissues—and potentially rewrite treatment paradigms. This technology will serve as a biomarker capable of advancing the clinical trials of BXT-25 because it is a powerful way to measure oxygen consumption of the brain during stroke.

"Bioxytran is poised to lead the oxygen therapeutics revolution," said Avraham Mayevsky, Member of Bioxytran’s Medical Advisory Board. "The principles in this book, tracing tissue oxygenation, could accelerate treatments for stroke, chronic wounds, and even Alzheimer’s—where restoring oxygen delivery may slow neurodegeneration."

About Bioxytran, Inc.

Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. When utilized by paramedics at the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over 90%. For more information, visit www.bioxytraninc.com

Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

FAQ

What is Bioxytran's (BIXT) new breakthrough in tissue oxygenation monitoring?

Bioxytran has developed technology for tissue-specific oxygenation monitoring, moving beyond traditional peripheral measurements to provide more accurate readings of oxygen levels in vital organs.

How will BIXT's technology impact stroke treatment?

The technology will serve as a biomarker in BXT-25 clinical trials, measuring brain oxygen consumption during stroke, potentially leading to more effective treatments through targeted oxygen delivery.

What markets is Bioxytran (BIXT) targeting with its oxygen monitoring technology?

Bioxytran is targeting markets including stroke treatment, Alzheimer's disease, and chronic wounds where precise oxygen delivery monitoring could improve patient outcomes.

Who is Prof. Avraham Mayevsky and what is his role at Bioxytran (BIXT)?

Prof. Mayevsky is a key advisor to Bioxytran and member of their Medical Advisory Board who published groundbreaking research on body oxygen homeostasis and mitochondrial function.

What is the significance of Bioxytran's MDX Viewer technology?

The MDX Viewer is an FDA-approved tool that enables tissue-specific oxygenation monitoring, offering more precise measurements than traditional peripheral oxygen monitoring methods.